Plain-English translation of NCT06526793 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called (AZD0486) as a treatment for adults with B-cell lymphoma that has come back or stopped responding to prior therapies. The study will give the medication through an IV infusion and measure how well it works and how safe it is. Researchers want to learn whether this medication can help people whose lymphoma has been difficult to treat.
Many people with B-cell lymphoma eventually stop responding to standard treatments, and their cancer comes back. This study exists to find out whether this new treatment can help patients in that difficult situation who have already tried other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive intravenous infusions of the medication at a dose that has been determined to be safe and effective. You will visit the study center regularly for treatment visits and follow-up appointments where doctors will monitor how you're doing and check for any side effects. The study involves two separate groups — one for people with follicular lymphoma and one for people with large B-cell lymphoma — and researchers will track how well the medication works for your specific type of cancer.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States